Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040053
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2002-06-18
Brief Title:
Ondansetron for the Treatment of Methamphetamine Dependence - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Double-Blind Placebo-Controlled Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence
Detailed Description:
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron 025 10 and 40 mg taken orally twice per day to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None